-
-
-
[1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] Zeng H,Chen W,Zheng R,et al.Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries[J].Lancet Glob Health,2018,6(5):e555-e567.
[3] Lam JS,Shvarts O,Leppert JT,et al.Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system[J].J Urol,2005,174(2):466-472.
[4] Gul A,Rini BI.Adjuvant therapy in renal cell carcinoma[J].Cancer,2019,125(17):2935-2944.
[5] Amin MB,Greene FL,Edge SB,et al.The Eighth Edition AJCC Cancer Staging Manual:Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J].CA Cancer J Clin,2017,67(2):93-99.
[6] Martínez-Salamanca JI,Huang WC,Millán I,et al.Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension[J].Eur Urol,2011,59(1):120-127.
[7] Patard JJ,Kim HL,Lam JS,et al.Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma:an international multicenter study[J].J Clin Oncol,2004,22(16):3316-3322.
[8] Sorbellini M,Kattan MW,Snyder ME,et al.A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma[J].J Urol,2005,173(1):48-51.
[9] Wu J,Jin S,Gu W,et al.Construction and validation of a 9-gene signature for predicting prognosis in stage Ⅲ clear cell renal cell carcinoma[J].Front Oncol,2019,9:152.
[10] Qu L,Wang ZL,Chen Q,et al.Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma[J].Eur Urol,2018,74(6):756-763.
[11] Messing EM,Manola J,Wilding G,et al.Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma:an Eastern Cooperative Oncology Group/Intergroup trial[J].J Clin Oncol,2003,21(7):1214-1222.
[12] Nandagopal L,Naik G,Sonpavde G.Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma[J].Curr Treat Options Oncol,2018,19(1):2.
[13] Haas NB,Manola J,Uzzo RG,et al.Adjuvant sunitinib or sorafenib for high-risk,non-metastatic renal-cell carcinoma(ECOG-ACRIN E2805):a double-blind,placebo-controlled,randomised,phase 3 trial[J].Lancet,2016,387(10032):2008-2016.
[14] Ravaud A,Motzer RJ,Pandha HS,et al.Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy[J].N Engl J Med,2016,375(23):2246-2254.
[15] Motzer RJ,Haas NB,Donskov F,et al.Randomized phase Ⅲ trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma[J].J Clin Oncol,2017,35(35):3916-3923.
[16] Gross-Goupil M,Kwon TG,Eto M,et al.Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma:results from the phase Ⅲ,randomized ATLAS trial[J].Ann Oncol,2018,29(12):2371-2378.
[17] Motzer RJ,Ravaud A,Patard JJ,et al.Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy:Subgroup Analyses and Updated Overall Survival Results[J].Eur Urol,2018,73(1):62-68.
[18] Haas NB,Manola J,Dutcher JP,et al.Adjuvant treatment for high-risk clear cell renal cancer:Updated results of a high-risk subset of the ASSURE randomized trial[J].JAMA Oncol,2017,3(9):1249-1252.
[19] Sun M,Marconi L,Eisen T,et al.Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma:A Systematic Review and Pooled Analysis[J].Eur Urol,2018,74(5):611-620.
[20] Ridyard DG,Buller DM,Ristau BT.The Current State of Adjuvant Therapy Following Surgery for High-risk Renal Cell Carcinoma[J].Eur Urol Focus,2019,5(6):935-938.
[21] 郑昱,魏迪,侯广东,等.无远处转移性肾癌患者术后辅助靶向治疗疗效和安全性的Meta分析[J].中华泌尿外科杂志,2019,40(3):171-177.
[22] 中华医学会泌尿外科学分会肾癌指南编写组.2015中国肾癌靶向治疗药物不良反应管理专家共识[J].中华泌尿外科杂志,2016,37(1):2-6.
-
计量
- 文章访问数: 613
- PDF下载数: 899
- 施引文献: 0
下载: